<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
"http://www.w3.org/TR/html4/strict.dtd">
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>

	<!-- Basic Page Needs
  ================================================== -->
    <script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/jquery-1.8.3.min.js" type="text/javascript"></script>
    <script type="text/x-mathjax-config">
	MathJax.Hub.Config({
	  "HTML-CSS": { linebreaks: { automatic: true } },
	         SVG: { linebreaks: { automatic: true } }
	});
	</script>
    <script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
	<meta charset="utf-8">
	<title>Heart &amp; Circulation</title>
	<meta name="description" content="Course Notes for Heart &amp; Circulation">
	<meta name="author" content="Kevan Lu">
	<meta name="robots" content="noindex,nofollow"/>
	
	<!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">

	<!-- CSS
  ================================================== -->
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/layout.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/content.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/print.css">
	<link href="http://maxcdn.bootstrapcdn.com/font-awesome/4.2.0/css/font-awesome.min.css" rel="stylesheet">	
	
	<script>
		(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
		(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
		m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
		})(window,document,'script','http://www.google-analytics.com/analytics.js','ga');		
		ga('create', 'UA-40381402-3', 'dropboxusercontent.com');
		ga('send', 'pageview');
	</script>

	<!-- Favicons
	================================================== -->
	<link rel="shortcut icon" href="https://dl.dropboxusercontent.com/u/157117/Class%20References/favicon.png" type="image/png">
</head>
<body>
    <div class="overlay"><h1><a style="border:none;" href="http://kevanlu.github.io/cardiology//index.html">Heart &amp; Circulation</a></h1></div>
    <div class="sidebar-background"></div>
    <div class="sidebar">
        <!-- Displays a Search Bar-->
<div class="search-wrapper">
	<div class="index"><a href="http://kevanlu.github.io"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<form class="search" action="http://kevanlu.github.io/cardiology/search.html">
	<div style="float: left;"><input type="text" value="Search Heart &amp; Circulation" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	<div style="float: left;"><input type="button" id="tipue_search_button" onclick="this.form.submit();"></div>
	<div style="clear: left;"></div>
	</form>
</div>

<div class="course-index">
	<a href="http://kevanlu.github.io/cardiology//index.html">Heart &amp; Circulation</a>
</div>

        <nav>	
	<li class="week">Week 1</li>
	<ul>
		<li class="day">January 13</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/13/intro-cardiac-physiology.html">Introduction to Cardiac Physiology</a></li></ul>
		<li class="day">January 14</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/14/intro-cardiac-physiology-2.html">Introduction to Cardiac Physiology II</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/14/heart-pump.html">The Heart as a Pump I</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/14/bp-reg-vascular-flow.html">BP Regulation &amp Vascular Flow</a></li></ul>
		<li class="day">January 15</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/15/cardiac-electrical-physiology.html">Cardiac Electrical Physiology</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/15/interpreting-ecgs-1a.html">Interpreting ECGs Ia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/15/interpreting-ecgs-1b.html">Interpreting ECGs Ib</a></li></ul>
		<li class="day">January 16</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/16/heart-pump-2.html">The Heart as a Pump II</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/16/heart-pump-3.html">The Heart as a Pump III</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/16/anatomy-lab-heart.html">Heart Anatomy Lab</a></li></ul>
		<li class="day">January 17</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/17/intro-cardiovascular-pharmacology.html">Cardiovascular Pharmacology I</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/17/intro-cardiovascular-pharmacology-2.html">Cardiovascular Pharmacology II</a></li></ul>
	</ul>
	<li class="week">Week 2</li>
	<ul>
		<li class="day">January 20</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/20/valvular-heart-disease-cases.html">Valvular Heart Disease Cases</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/20/imaging-cardiovascular-disease.html">Imaging in Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/20/into-heart-sounds.html">Introduction to Heart Sounds</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/20/clinical-assessment-heart-sounds.html">Clinical Assessment of Heart Sounds</a></li></ul>
		<li class="day">January 21</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/21/aortic-stenosis.html">Aortic Stenosis</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/21/mitral-regurgitation.html">Mitral Regurgitation</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/21/mitral-stenosis.html">Mitral Stenosis</a></li></ul>
		<li class="day">January 22</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/22/aortic-regurgitation.html">Aortic Regurgitation</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/22/endocarditis.html">Endocarditis</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/22/interpreting-ecgs-2.html">Interpreting ECGs II</a></li></ul>
		<li class="day">January 23</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/23/outline-congenital-heart-disease.html">An Outline of Congenital Heart Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/23/exercise-physiology.html">Exercise Physiology</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/23/valvular-pericardial-cases.html">Valvular Pericardial Cases</a></li></ul>
		<li class="day">January 24</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/24/surgical-management-valvular-disease.html">Surgical Management in Valvular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/24/case-based-learning.html">Case Based Learning</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/24/clinical-problems-pediatric-cardiology.html">Clinical Problems in Pediatric Cardiology</a></li></ul>
	</ul>
	<li class="week">Week 3</li>
	<ul>
		<li class="day">January 27</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/27/case-based-learning-atherosclerosis.html">Atherosclerosis Case Based Learning</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/27/investigations-ischemic-heart-disease.html">Investigations in Ischemic Heart Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/27/vascular-pathology.html">Vascular Pathology</a></li></ul>
		<li class="day">January 28</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/28/cholinergic-pharmacology-1.html">Cholinergic Pharmacology I</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/28/physiology-hypertension.html">Physiology of Hypertension</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/28/microcirculation-physiology.html">Microcirculation Physiology</a></li></ul>
		<li class="day">January 29</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/29/pharmacology-dyslipidemia.html">Pharmacology for Dyslipidemia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/29/lipids-genes-CAD.html">Lipids, Genes, and CAD</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/29/anatomy-lab-mediastinum.html">Mediastinum Anatomy Lab</a></li></ul>
		<li class="day">January 30</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/30/aneurysms.html">Aneurysms</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/30/case-based-learning-peripheral-vascular-disease.html">Peripheral Vascular Disease Cases</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/30/management-hypertension.html">Management of Hypertension</a></li></ul>
		<li class="day">January 31</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/31/vascular-small-group.html">Vascular Small Group Session</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/31/hypertension-small-group.html">Hypertension Small Group Session</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/01/31/cholinergic-pharmacology-2.html">Cholinergic Pharmacology II</a></li></ul>
	</ul>
	<li class="week">Week 4</li>
	<ul>
		<li class="day">Monday, February 3</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/03/primary-prevention-cardiovascular-disease.html">Primary Prevention of Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/03/secondary-prevention-cardiovascular-disease.html">Secondary Prevention of Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/03/management-chronic-coronary-disease.html">Management of Chronic Coronary Disease</a></li></ul>
		<li class="day">Tuesday, February 4</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/04/coronary-circulation.html">Coronary Circulation</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/04/coronary-artery-disease-mi-pci-1.html">Coronary Artery Disease &mdash; MI &amp; PCI I</a></li></ul>
		<li class="day">Wednesday, February 5</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/05/nutrition-cardiovascular-disease.html">Nutrition and Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/05/ischemic-heart-disease-pathology.html">Ischemic Heart Disease Pathology</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/05/coronary-artery-disease-mi-pci-2.html">Coronary Artery Disease &mdash; MI &amp; PCI II</a></li></ul>
		<li class="day">Thursday, February 6</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/06/pediatric-cardiology.html">Child Health &mdash; Pediatric Cardiology</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/06/chest-pain-small-group.html">Chest Pain Small Group</a></li></ul>
		<li class="day">Friday, February 7</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/07/surgical-management-cardiovascular-disease.html">Surgical Management of Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/07/intervention-cardiac-patient-cases.html">Intervention in Cardiac Patient Cases</a></li></ul>
	</ul>
	<li class="week">Week 5</li>
	<ul>
		<li class="day">Monday, February 10</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/10/heart-failure-cases.html">Heart Failure Cases</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/10/heart-failure-1.html">Heart Failure I</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/10/physiology-heart-failure.html">Physiology of Heart Failure</a></li></ul>
		<li class="day">Tuesday, February 11</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/11/heart-failure-2.html">Heart Failure II</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/11/heart-failure-3.html">Heart Failure III</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/11/heart-failure-small-groups.html">Heart Failure Small Groups</a></li></ul>
		<li class="day">Wednesday, February 12</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/12/mechanism-arrythmia.html">Mechanism of Arrythmia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/12/antiarrythmics.html">Antiarrythmics</a></li></ul>
		<li class="day">Thursday, February 13</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/13/atrial-fibrillation.html">Atrial Fibrillation</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/13/supraventricular-tachycardia.html">Supraventricular Tachycardia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/13/ventricular-tachycardia.html">Ventricular Tachycardia</a></li></ul>
		<li class="day">Friday, February 14</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/14/interpreting-ecgs-3.html">Interpreting ECGs III &mdash; Cases</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/14/bradycardia.html">Bradycardia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/14/syncope.html">Syncope</a></li></ul>
	</ul>
	<li class="week">Week 6</li>
	<ul>
		<li class="day">Tuesday, February 18</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/18/end-of-life-care.html">End of Life Care</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/18/arrythmia-small-groups.html">Arrythmia Small Groups</a></li></ul>
		<li class="day">Wednesday, February 19</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/19/ecg-exercises.html">ECG Exercises</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/19/integrated-wrap-up-cases.html">Integrated Wrap-up Cases</a></li></ul>
		<li class="day">Thursday, February 20</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology//2014/02/20/exam-review-cardiovascular-jeopardy.html">Final Exam Review</a></li></ul>
	</ul>
</nav>
    </div>
    <div class="content-offset">
        <div class="content-background"></div>
        <div class="content">
             <div class="single post">
                <!-- Post Layout -->
                <div class="title"><h1>Cholinergic Pharmacology II</h1></div>
                <info datetime="2014-01-31">
                    <span class="author"><a href="https://dl.dropboxusercontent.com/u/157117/notes-reference/jekyll/_site/contributors.html#kevanlu">Kevan Lu</a></span>
                    <span class="date">Friday, January 31, 2014</span>
                </info>
                <div class="body"><h1 id='outline_of_cholinergic_drugs'>Outline of Cholinergic Drugs</h1>
<hr />
<h4 id='cholinomimetic_drugs'><strong>Cholinomimetic Drugs</strong></h4>

<ol>
<li>
<p><strong>Direct Acting</strong> &#8594; bind directly to Ach receptors</p>

<ul>
<li><em>Muscarinic Receptors</em> &#8594; eg. <strong>Bethanechol Chloride (Duvoid)</strong></li>

<li><em>Nicotinic Receptors</em> &#8594; eg. <strong>Nicotine</strong></li>
</ul>
</li>

<li>
<p><strong>Indirect Acting</strong> &#8594; inhibit Acetylcholinesterase. Increases both <em>muscarinic</em> and <em>nicotinic</em> activation.</p>

<ul>
<li><em>Reversible</em></li>

<li><em>Irreversible</em></li>
</ul>
</li>
</ol>

<h4 id='cholinoceptor_blocking_drugs'><strong>Cholinoceptor Blocking Drugs</strong></h4>

<ol>
<li>
<p><strong>Muscarinic Receptor Blockers</strong> &#8594; <strong>Atropine</strong></p>
</li>

<li>
<p><strong>Neuromuscular Blockers</strong> &#8594; the class of nicotinic receptors that are at NMJs.</p>

<ul>
<li><em>Depolarizing</em> &#8594; <strong>Succinylcholine</strong></li>

<li><em>Non-Depolarizing</em> &#8594; <strong>Curare</strong></li>
</ul>
</li>
</ol>

<h1 id='cholinomimetic_drugs'>Cholinomimetic Drugs</h1>
<hr />
<h2 id='direct_acting_drugs'><strong>Direct Acting Drugs</strong></h2>

<ul>
<li>
<p>Why do we use <em>cholinomimetic</em> drugs?</p>

<ul>
<li><em>Acetylcholine itself has no therapeutic effect</em> &#8212; it breaks down too quickly!</li>

<li>However, the cholinergic response can be manipulated with Ach-like drugs with longer half lifes.</li>
</ul>
</li>
</ul>

<h3 id='1_muscarinic_receptors'>1. <strong>Muscarinic Receptors</strong></h3>

<ul>
<li>
<p>One example is <strong>Bethanechol chloride (Duvoid)</strong></p>

<ul>
<li><em>muscarinic agonist</em></li>

<li>acts against the parasympathetic nervous system, as well as sweat glands in the sympathetic.</li>

<li><strong>Urinary bladder stimulant</strong></li>
</ul>
</li>

<li>
<p>As a consequence, what side effects would you expect?</p>

<ul>
<li><em>Increased sweating</em> &#8594; because of sympathetic innervation of the sweat glands by muscarinic receptors.</li>

<li>In the lungs, the parasympathetic response would be <em>bronchoconstriction.</em></li>

<li><em>Fall in the heart rate</em>.</li>

<li>Also, effects on <strong>SLUDGE</strong> (salivation, lacrimation, urination, defecation, gastrointestinal emesis).</li>
</ul>
</li>

<li>
<p>As a result, Duvoid is contraindicated in those with bradycardia.</p>
</li>

<li>
<p>A mushroom called <strong>Aminida muscaria</strong> is also a muscarinic agonist.</p>
</li>

<li>
<p>Hence, mushroom poisoning with this gives you all the same effects.</p>
</li>

<li>
<p>They&#8217;re also part of class of drugs known as &#8216;Magic Mushrooms&#8217; due to CNS effects in the brain!</p>
</li>
</ul>

<h3 id='2_nicotinic_receptors'>2. <strong>Nicotinic Receptors</strong></h3>

<ul>
<li>The obvious nicotinic receptor agonist is <strong>nicotine</strong>.</li>

<li>Recall that nicotinic receptors are in the ganglia, NMJs, and CNS.</li>
</ul>
<span class='sidenote'>Recall that the nicotinic receptors in the ganglia and CNS are different from those at the neuromuscular junctions, and can be targeted differently.</span>
<ul>
<li>
<p>As a medication, <em>nicotine</em> itself mostly affects the CNS and ganglia, and not so much the neuromuscular junctions (unless in toxic doses).</p>

<ul>
<li>Initially, nicotine will stimulate these receptors to <em>increase sympathetic tone</em> (recall that the ganglia for both the SNS and PSNS are have cholinergic nerves with <em>nicotinic receptors</em>).</li>

<li>It will also stimulate the release of <em>epinephrine</em> and <em>norepinephrine</em> from the adrenal.</li>

<li>As we have more toxic doses, the effect on the parasympathetic ganglia will begin to dominate, so we&#8217;ll see some salivation, diarrhea, etc.</li>

<li>After extremely high ingestion, we can see muscle paralysis by acting on the NMJs and causing a <em>blockage</em> of transmission.</li>
</ul>
</li>

<li>
<p>Consequently, nicotine has a very <em>dose-dependent effect</em>.</p>
</li>
</ul>
<hr />
<h2 id='indirect_acting_drugs'><strong>Indirect Acting Drugs</strong></h2>

<ul>
<li>
<p>The indirect cholinomimetic drugs <em>inhibit acetylcholinesterase (AchE)</em>.</p>
</li>

<li>
<p>Hence they&#8217;re also known as <strong>anticholinesterases</strong>.</p>
</li>

<li>
<p>They inhibits Acetylcholinesterase (AchE) by preventing Ach binding.</p>
</li>

<li>
<p>Because Ach is also a neurotransmitter, if the drug crosses the blood-brain barrier, it can also cause CNS effects.</p>
</li>

<li>
<p>Since anticholinesterases result in the <em>accumulation of Ach</em> in the synapse, there will be stimulation of <em>both the muscarinic and nicotinic receptors</em>.</p>
</li>

<li>
<p>As a result, we have <em>very messy pharmacological efects</em>.</p>

<ol>
<li><em>Muscarinic Response</em> (parasympathetic) &#8594; <strong>SLUDGE</strong></li>

<li><em>Nicotinic Response</em> &#8594; activation of the NMJ, and autonomic effects because of effects on the ganglia.</li>

<li><em>CNS Effects</em>, if we have crossing of the <em>Blood Brain Barrier (BBB)</em>. This could lead to psychosis and seizures in toxic doses.</li>
</ol>
</li>

<li>
<p>Consequently, when we use these drugs clinically, we have to be very careful with the dosage.</p>
</li>
</ul>

<h3 id='1_reversible_anticholinesterases'>1. <strong>Reversible Anticholinesterases</strong></h3>

<ul>
<li><strong>Simple alcohols</strong></li>

<li><strong>Carbamates</strong>.</li>

<li><strong>Neostigmine</strong> is one good example we saw in ITM.</li>
</ul>

<h3 id='2_irreversible_anticholinesterases'>2. <strong>Irreversible Anticholinesterases</strong></h3>

<ul>
<li><strong>Organophosphates</strong></li>

<li>An example of this would be the <em>Sarin</em> nerve gas.</li>
</ul>

<h4 id='anticholinesterase_therapy'><strong>Anticholinesterase Therapy</strong></h4>

<ol>
<li>
<p><strong>Glaucoma</strong> &#8594; we use the PSNS to cause <em>miosis</em> (pupil constriction), to improve flow, and reduce pressure.</p>
</li>

<li>
<p><strong>Myasthenia Gravis</strong></p>

<ul>
<li>Recall that Myasthenia Gravis is a Type II Hypersensitivity reaction resulting in antibodies against the Acetylcholine receptors.</li>

<li>Can present with <strong>ptosis</strong> &#8594; dropping of the eyelid.</li>

<li>Causes impaired muscle contraction, and weakness.</li>

<li>We use anticholinesterases to compensatorily increase Ach levels to improve muscle function.</li>

<li>Typical anticholinesterases for this don&#8217;t cross the BBB, obviously.</li>
</ul>
</li>

<li>
<p><strong>Treatment of Dementia/Cognitive Impairment</strong></p>

<ul>
<li>
<p>Obviously here we aim for the drug to cross the BBB, where it has its function.</p>
</li>

<li>
<p>Not useful with mild cognitive impairment, no improvement in function but lots of side effects!</p>

<ul>
<li>Side effects include muscarinic effects (<em>SLUDGE</em>)</li>

<li>There are also nicotinic effects &#8594; sympathetic enervation causing BP and HR changes</li>
</ul>
</li>
</ul>
</li>
</ol>

<h1 id='cholinoceptor_blocking_drugs'>Cholinoceptor Blocking Drugs</h1>
<hr />
<h2 id='muscarinic_receptor_antagonists'><strong>Muscarinic Receptor Antagonists</strong></h2>
<span class='sidenote'>Atropos is the third of the 'Three Fates', daughters of Zeus. Atropos cuts the thread of life! A pretty unfortunate name.</span>
<ul>
<li>One example is <strong>Atropine</strong></li>

<li>Atropine is used to <em>increase heart rate</em>, by blocking vagal enervation of the heart.</li>

<li>This makes sense, since it &#8595;PSNS, it should be similar to &#8593;SNS!</li>

<li>It&#8217;s toxic in large doses.</li>

<li>Note that Atropine <em>does not induce muscle weakness</em>. It only acts on the muscarinic receptors, so it doesn&#8217;t affect the nicotinic receptors at the neuromuscular junctions.</li>

<li>It will cause <em>tachycardia</em>, <em>dry mouth</em>, etc. (anti-PSNS effects).</li>

<li>Atropine would also be used to treat <em>muscarinic toxicity</em> (eg. because someone ate a magic mushroom).</li>

<li>It would also be used to treat <em>acetylcholinesterase toxicity</em> to block the <em>muscarinic effect</em> (we don&#8217;t have anything that can specifically block the nicotinic ganglionic effect as of yet).</li>
</ul>

<h3 id='anticholinergic_toxidrome_antimuscarinic_toxidrome'><strong>Anticholinergic Toxidrome (Antimuscarinic Toxidrome)</strong></h3>

<ul>
<li>
<p>This describes the set of <em>side-effects we have from muscarinic antagonism:</em></p>

<ul>
<li><strong>Hot as a hare</strong> &#8594; people are no longer able to sweat, can&#8217;t thermoregulate.</li>

<li><strong>Dry as a bone</strong> &#8594; also because they can&#8217;t sweat anymore. Also, since we block salivation (the S in SLUDGE), we have a dry mouth.</li>

<li><strong>Red as a beet</strong> &#8594; flushing due to systemic vasodilation. (recall that the SNS causes systemic vasoconstriction and skeletal muscle vasodilation)</li>

<li><strong>Blind as a bat</strong> &#8594; pupil dilation affects the reflex of accomodation.</li>

<li><strong>Mad as a hatter</strong> &#8594; if the muscarinic antagonist passes the BBB, which atropine does, it can cause CNS effects.</li>
</ul>
</li>

<li>
<p>Surprisingly, a lot of medications we have nowadays have anticholinergic (antimuscarinic) effects.</p>
</li>

<li>
<p>Some examples include <strong>Gravol</strong> and <strong>Benadryl</strong> (diphenhydramine).</p>
</li>

<li>
<p>These drugs can predispose elderly patients to delirium!</p>
</li>

<li>
<p>For instance, <strong>Tolterodine</strong> (Detrol), which is a competitive muscarinic receptor antagonist, is used for overactive bladder, by decreasing vagal stimulation of the bladder.</p>
</li>

<li>
<p><em>What side effects would you expect by inhibiting the PSNS?</em></p>

<ul>
<li>Dry mouth, constipation, blurry vision (blind as a bat), flushing, etc.</li>
</ul>
</li>

<li>
<p>Because of this, there&#8217;s a risk of causing a <em>prescribing cascade</em>, especially since muscarinic antagonists have such diverse side-effects.</p>
</li>

<li>
<p>Another muscarinic receptor antagonist is <strong>Ipratropium Bromide</strong> &#8594; used as a bronchodilator.</p>
</li>
</ul>

<blockquote>
<h3 id='muscarinic_receptor_antagonists'><strong>Muscarinic Receptor Antagonists</strong></h3>

<ul>
<li><strong>Atropine</strong>.</li>

<li><strong>Tolterodine</strong> &#8594; used for an overactive bladder.</li>

<li><strong>Ipratropium Bromide</strong> &#8594; used as a bronchodilator.</li>
</ul>
</blockquote>
<hr />
<h2 id='nicotinic_receptor_antagonists'><strong>Nicotinic Receptor Antagonists</strong></h2>

<ul>
<li>
<p>These are all <strong>neuromuscular blockers</strong>.</p>
</li>

<li>
<p>We don&#8217;t use drugs that block ganglionic function anymore because they had too many side-effects, affecting both the SNS and PSNS. (Since all the ganglia are cholinergic, and feed to neurons with nicotinic receptors).</p>
</li>

<li>
<p>Classes of nicotinic receptor antagonists include:</p>

<ol>
<li><strong>Depolarizing</strong></li>

<li><strong>Non-depolarizing</strong></li>
</ol>
</li>
</ul>

<h3 id='1_depolarizing_neuromuscular_blockers'>1. <strong>Depolarizing Neuromuscular Blockers</strong></h3>

<ul>
<li>
<p><strong>Succinylcholine</strong> &#8594; blocks depolarization, causing <em>muscle paralysis</em>.</p>

<ul>
<li>Structurally, succinylcholine looks like two Ach molecules stuck together.</li>

<li>This lets them bind specifically to the NMJ cholinergic receptors, but because they&#8217;re structurally different, they aren&#8217;t rapidly broken down by acetylcholinesterases.</li>

<li>This depolarizes the muscle, causing <em>muscle fasciculations</em>.</li>

<li>But because it isn&#8217;t broken down rapidly, the muscles are <em>transiently paralyzed</em>.</li>

<li>This gives you a brief period of muscular paralysis (around 5 minutes).</li>

<li>Clinically, this is used to <em>help intubate a patient</em>.</li>
</ul>
</li>
</ul>

<h3 id='2_nondepolarizing_neuromuscular_blockers'>2. <strong>Non-depolarizing Neuromuscular Blockers</strong></h3>

<ul>
<li>These are competitive antagonists at the neuromuscular junction.</li>

<li>The archetypical example of this is <strong>curare</strong>, although it&#8217;s not used medically anymore.</li>

<li>They bind to nicotinic receptors, but <em>don&#8217;t cause depolarization</em> (compared to Succinylcholine).</li>

<li>This results in muscle paralysis as well, but it has a <em>slower onset</em> and a <em>longer duration of effect</em>.</li>
</ul>

<h4 id='how_do_we_reverse_this_effect'><strong>How do we reverse this effect?</strong></h4>

<ul>
<li>If we have a drug that is <em>blocking</em> neuromuscular conduction via competitive antagonism, we can simply increase the levels of Acetylcholine.</li>

<li>This can be done with an <strong>anticholinesterase</strong>.</li>

<li>This is usually combined with <strong>atropine</strong> to block the <em>muscarinic effects</em> of the anticholinesterase. (recall that because it increases Ach everywhere, it stimulates both nicotinic and muscarinic innervation)</li>

<li><em>This is done when we wake someone up from anesthesia!</em></li>
</ul>

<blockquote>
<h3 id='case_study'><strong>Case Study</strong></h3>

<p>Consider this <a href='http://www.youtube.com/watch?v=JylK4HuKMvQ'>Sick Triceratops</a> (ahaha!). Why was he sick?</p>

<p>His symptoms included:</p>

<ul>
<li>Dilated pupils.</li>

<li>Dry tongue.</li>

<li>Absent bowel sounds.</li>

<li>Urinary retention.</li>

<li>Not sweating.</li>

<li>Confused.</li>
</ul>

<h4 id='choices'><strong>Choices</strong></h4>

<ol>
<li>Acetylcholinesterase inhibitor.</li>

<li>Sympathomimetic agent.</li>

<li><em>Antocholinergic (antimuscarinic) agent.</em></li>

<li>Nicotinic receptor blocker.</li>

<li>Nicotine toxicity.</li>
</ol>
</blockquote>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/i646kf65.png' />
<ul>
<li>These are the effects you would see when you block <em>muscarinic</em> innervation.</li>

<li>Sometimes it&#8217;s difficult to differentiate between a <strong>sympathomimetic agent</strong> and an <strong>antimuscarinic agent</strong> &#8594; both increase the SNS:PSNS ratio, except at the <em>sweat glands</em>.</li>

<li>Hence, the key to differentiating between these is the <strong>sweating</strong>. With a sympathomimetic agent, you will have sweating, but with the antimuscarinic one, you won&#8217;t!</li>
</ul>                
                </div>
            </div>
            <div class="pagination">
                <div style="width:50%; float:left;">
                     
                        <a class="newer" href="http://kevanlu.github.io/cardiology//2014/01/31/hypertension-small-group.html"><i class="fa fa-angle-left"></i> Hypertension Small Group Session</a> 
                     
                </div>
                <div style="width:50%; float:right;">
                     
                        <a class="older" href="http://kevanlu.github.io/cardiology//2014/02/03/primary-prevention-cardiovascular-disease.html">Primary Prevention of Cardiovascular Disease <i class="fa fa-angle-right"></i></a> 
                     
                </div>
            </div>
        </div>
    </div>
    <script src="http://kevanlu.github.io/cardiology//index.js" type="text/javascript"></script>
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/search.css">	
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch_set.js" type="text/javascript"></script>
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch.js" type="text/javascript"></script>

<script>
$(document).ready(function() {
     $('#tipue_search_input').tipuesearch();
});
</script>
</body>
</html>